Dr. Reddy’s Laboratories: Strong Growth, Rising Capex, But Is the Market Missing the Story?

Date:

Share post:

🔬 Dr. Reddy’s Laboratories Ltd is showing all the right signs of aggressive expansion.
Despite a decline in EBITDA margins this year, the company has:

✔️ Maintained steady sales growth
✔️ Increased borrowings (₹2,002 Cr → ₹4,677 Cr) to fund capex
✔️ Grown its fixed assets from ₹10,426 Cr to ₹18,293 Cr — a clear sign of future capacity expansion
✔️ Managed operating expenses well

⚠️ However, rising trade receivables remain a concern — a key area where management needs to focus.

📉 Interestingly, the stock’s price CAGR is lagging behind the company’s strong compound sales and profit growth.
➡️ This could be an opportunity — the stock appears undervalued at current levels.

💡 Is the market underestimating Dr. Reddy’s long-term growth story?

Let me know your thoughts in the comments! 👇

DRREDDY REPORT

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

MTAR Technologies: Rising Costs, Falling Profits, and Promoter Exit – Time to Reassess?

MTAR Technologies har quarter naye bade targets announce karti hai – ₹700 Cr+ revenue, 28% EBITDA margin, aur...

HUL: Sleeping Giant Ready to Break Out?

📈 Equity Research Update: Hindustan Unilever Ltd (HUL) Over the past 2–3 years, HUL’s stock has been consolidating in...

Pharma Sector Financial Overview

📊 Pharma Sector Financial Overview: Key Insights from the Latest Report 💊 🔹 Fixed Assets & Borrowings – How...

Shipbuilding Industry – A Perfect Cyclical Opportunity?

🚢 Shipbuilding Industry – A Perfect Cyclical Opportunity? Just completed an in-depth research report on the Global Shipbuilding Cycle,...
WhatsApp chat